Clinical trials: Hemostatic Disorders
Severe Hemophilia A With Inhibitor
Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
This is an observational, prospective, longitudinal, multicenter, cohort study designed with the scope to verify whether or not TGA may predict effectiveness of different FVIII concentrates class (devoid or rich of VWF) in…
- Trial name
- PredicTGA (NCT01505946)
- Testing
- TGA (Thrombin generation Assay)
- Where
- 15 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Grifols Italia S.p.A
Heart Failure, Multiple Myeloma
Prospective Observation of Cardiac Safety With Proteasome Inhibition
The purpose of this study is to better define and understand potential cardiac toxicities of proteasome inhibitors and to understand optimal management strategies to treat and prevent cardiovascular events.
- Trial name
- PROTECT (NCT02178579)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Vanderbilt University Medical Center
Multiple Myeloma
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
This is an open-label, phase 1 study to assess the safety, pharmacodynamics, and anti-myeloma effects of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCRζ and…
- Trial name
- NCT03549442
- Testing
- BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma, Relapsed/Refractory
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
This is a phase 2 study to see how effective investigational drug, JNJ-42756493, is when given in combination with dexamethasone in two groups of patients with multiple myeloma (cancer of the plasma cells, a type of white blood…
- Trial name
- NCT02952573
- Testing
- JNJ-42756493, Dexamethasone
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Multiple Myeloma
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01155583
- Testing
- azacitidine, lenalidomide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Case Comprehensive Cancer Center
Trauma, Hemorrhage
Fibrinogen Early In Severe Trauma studY Junior
1. Haemorrhage in severe trauma is a significant cause of mortality and is potentially the most preventable cause of death in paediatric trauma patients 2.
- Conditions
- Trauma, Hemorrhage, Coagulopathy, Pediatrics
- Trial name
- FEISTY Jnr (NCT03508141)
- Testing
- Fibrinogen Concentrate, Cryoprecipitate
- Where
- 10 sites in Australia
- Volunteers
- 44 people
- Sponsor
- Gold Coast Hospital and Health Service
Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM)
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.
- Conditions
- Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT02265731
- Testing
- azacitadine, venetoclax, rituximab / IDEC-C2B8
- Where
- 14 sites in Japan
- Volunteers
- 38 people
- Sponsor
- AbbVie
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
This is a phase I clinical study to evaluate the safety and tolerability of C-4-29 in patients with relapsed or refractory multiple myeloma, and to obtain the maximum tolerated dose of C-4-29 and phase II Recommended dose.
- Trial name
- NCT04861480
- Testing
- C-4-29 Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Post Partum Hemorrhage, Fibrinogenolysis; Hemorrhage
Patient Blood Management for Massive Obstetric Hemorrhage
Obstetric Hemorrhage continues to be the first cause of maternal morbidity and mortality around the world especially in middle to low income countriesThe blood components are high value resources; however, its use has been shown…
- Conditions
- Post Partum Hemorrhage, Fibrinogenolysis; Hemorrhage, Fibrinogen; Deficiency, Acquired, Massive Hemorrhage
- Trial name
- NCT03784794
- Testing
- Thromboelastometry, Standard Coagulation Test, Fibrinogen Concentrate Human
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Angel Augusto Perez Calatayud
Shift-Work Related Sleep Disturbance, Inflammation
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
The goal of this observational study is to learn if acutely and/or chronically altered sleep induces inflammation and/or a pro-thrombotic state (a tendency to form clots) in hospital workers who either work in shifts or are…
- Conditions
- Shift-Work Related Sleep Disturbance, Inflammation, Hemostatic Disorder, Sleep Disorder
- Trial name
- IPNO (NCT05775731)
- Testing
- Tests for markers of inflammation and activated hemostasis
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centro Cardiologico Monzino
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells.
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT05003141
- Testing
- PSB202
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 110 people
- Sponsor
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Multiple Myeloma
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT01522872
- Testing
- TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Threshold Pharmaceuticals
Multiple Myeloma
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.
- Trial name
- NCT00083577
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of Arkansas
Multiple Myeloma
Safety and Efficacy Assessments of Osalmid in Multiple Myeloma
This study aims to evaluate the safety and efficacy of a traditional cholagogue drug osalmid, 2-hydroxy-N-(4-hydroxyphenyl)-benzamide, in the treatment of multiple myeloma (MM).
- Trial name
- NCT03670173
- Testing
- Osalmid
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 10th People's Hospital
Multiple Myeloma
A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
Four monthly treatments with pegylated liposomal doxorubicin, thalidomide and dexamethasone for newly diagnosed myeloma patients as induction therapy prior to high dose chemotherapy and autologous stem cell transplant.
- Trial name
- NCT00222105
- Testing
- Doxil, Thalidomide, Dexamethasone
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Multiple Myeloma, Effects of Chemotherapy
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.
- Trial name
- GBRAM003r (NCT03402295)
- Testing
- Bortezomib, cyclophosphamide, thalidomide, dexamethasone
- Volunteers
- 311 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Prostheses and Implants, Stroke
Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
Mechanical heart valves (MHV) demand lifelong anticoagulation with vitamin K antagonists (VKA) due to the high thrombogenicity of the prosthesis.
- Conditions
- Prostheses and Implants, Stroke, Valve Heart Disease, Anticoagulants and Bleeding Disorders
- Trial name
- RIWA (NCT03566303)
- Testing
- Rivaroxaban 15 mg, Warfarin
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital Geral Roberto Santos
Coagulation Protein Disorders, Blood Loss, Surgical
Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)
Beriplex® P/N is made from human plasma (the liquid part of the blood) and contains the coagulation factors II, VII, IX and X which are important for blood clotting (coagulation).
- Conditions
- Coagulation Protein Disorders, Blood Loss, Surgical, Perioperative Care
- Trial name
- NCT01053169
- Testing
- Beriplex® P/N, Fresh Frozen Plasma (FFP) and Beriplex® P/N, Fresh Frozen Plasma
- Where
- 6 sites in United Kingdom
- Volunteers
- 445 people
- Sponsor
- CSL Behring
Multiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- NCT05372354
- Testing
- CC-92480, Tazemetostat, BMS-986158
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.